This is particularly noteworthy, as a JNK inhibitor was shown to reduce synaptic dysfunction and improve cognitive outcomes in mouse models of Alzheimer’s disease [41–43], and recent work showed genetically impairing JNK activation improves outcomes in ALS and Alzheimer’s models [44]. The gene discussed is MAPK8; the disease is early-onset autosomal dominant Alzheimer disease.